Clinical Utility of Liquid Biopsy as a tool to assess the evolution of brigatinib treated patients with non-small cell lung cancer with EML4-ALK translocation: an exploratory study (CUBIK)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511317-38-00

Enrollment

Registered

2024-03-11

Start date

2020-05-04

Completion date

Unknown

Last updated

2025-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALK+ non-small cell lung cancer

Brief summary

Overall response rate

Detailed description

Duration of response (DOR), Intracranial overall response rate, PFS rate at 1 year and 2 years, Overall Survival (OS) rate at 1 year and 2 years, Safety and tolerability of brigatinib

Interventions

DRUGAlunbrig 30 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall response rate	—

Secondary

Measure	Time frame
Duration of response (DOR), Intracranial overall response rate, PFS rate at 1 year and 2 years, Overall Survival (OS) rate at 1 year and 2 years, Safety and tolerability of brigatinib	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026